# RIGERNA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rigerna

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.rigerna.com/
- Total disclosed funding: $14M
- Latest round: Angel (Oct 21, 2024)
- Investors on record: 5

## About

Based in Suzhou, China, and founded in 2022, Suzhou Xuanjing Biotechnology Co., Ltd., trading as RIGERNA, is a nucleic acid pharmaceutical company focusing on the research and development of small nucleic acid drugs. In 2022, the company acquired Zhongguancun High-tech Enterprise Certificate. In August 2024, the company's liver-targeted siRNA drug pipeline RG002C0106 for complement C3 has obtained clinical approval in Australia and China. In March 2026, RIGERNA raised CNY 200 million in pre-series A funding led by Kangjun Capital, with participation from Delian Capital, Huatai Zijin Investment, Sealand Innovation, Lenovo Capital and Incubator Group, and Guolian Group, GSR United Capital.

The Company has three major platforms which are RIHOST®, RICMO® and LICOD®. Ricmo® focuses on improving accounting drug activity and improving off target effects.

The company generates revenue by developing small nucleic acid drugs.

## Funding rounds

- Angel, Oct 21, 2024, $14M — State Science & Technology Investment, GSR United Capital, Qihang Venture, Trinity Innovation Fund, Suzhou Xincheng Private Equity Fund Management

## Investors

- State Science & Technology Investment (https://capitalatlas.ai/funds/state-science-technology-investment) — Angel
- GSR United Capital (https://capitalatlas.ai/funds/gsr-united-capital) — Angel
- Qihang Venture (https://capitalatlas.ai/funds/qihang-venture) — Angel
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Angel
- Suzhou Xincheng Private Equity Fund Management (https://capitalatlas.ai/funds/suzhou-xincheng-private-equity-fund-management) — Angel